Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.
Abstract
The opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling. Aberrant transcription due to altered expression or mutation of genes that encode HATs, HDACs or their binding partners, is a key event in the onset and progression of cancer. HDAC inhibitors can reactivate gene expression and inhibit the growth and survival of tumour cells. The remarkable tumour specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylation of the core histones of nucleosomes strongly influences gene transcription (Khochbin et al., 2001; Johnstone, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Class I HDACs are ubiquitously expressed and are primarily located in the nucleus, while the class II enzymes can shuttle between the nucleus and cytoplasm and demonstrate tissue-specific expression (Johnstone, 2002; Marks et al., 2001; Vigushin and Coombes, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Two related classes of eukaryotic zinc-containing HDACs have been recognized based upon sequence similarity: class I (HDAC1, 2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) (Johnstone, 2002; Gao et al., 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“In general terms, condensed chromatin mediates transcriptional repression, whereas transcriptionally active genes are in areas of open chromati”
BackgroundCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“pl?locus=sir2">Sir2 , a yeast transcriptional repressor that requires the cofactor NAD + for its deacetylase activit”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“gov/cancer_information/cancer_type/leukemia/">leukaemias and solid tumours to express differentiated characteristics and stop proliferatin”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780 · cited 5×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundInfluential
Research works printed but not linked: 1
- Ruefli, A. A. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-gp expressing cells. Int. J. Cancer. (in the press).
Cited by
Items 201–300 of 1,001
Stockhausen, M.-T., Sjölund, J., Manetopoulos, C., & Axelson, H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602309 · Cited by 128
“Several lines of evidence indicate that aberrant acetylation of chromatin can contribute to tumorigenesis (Johnstone, 2002).”
Camphausen, K., Scott, T., Sproull, M., & Tofilon, P. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0537 · Cited by 128
Tang, R., Faussat, A., Majdak, P., Jy, P., Chaoui, D., Legrand, O., & Marie, J. (2004) · Leukemia · doi:10.1038/sj.leu.2403390 · Cited by 139
Shang, S., & Tan, D. S. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.03.006 · Cited by 142
Yang, K., Wu, H., Zhang, Z., Leisten, E. D., Nie, X., Liu, B., Wen, Z., Zhang, J., Cunningham, M. D., & Tang, W. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00046 · Cited by 124
Vishwakarma, S., Iyer, L. R., Muley, M. M., Singh, P., Shastry, A., Saxena, A., Kulathingal, J., Vijaykanth, G., Raghul, J., Rajesh, N., et al. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.03.016 · Cited by 124
“Histone Deacetylase inhibitors (HDACi) were initially studied for their ability to increase gene expression, however today there is increasing number of orally active, synthetic HDACi being primarily developed to treat cancer [1,2].”
BackgroundThe Epigenome as a Target for Cancer Chemoprevention
Kopelovich, L., Crowell, J. A., & Fay, J. R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dig109 · Cited by 133
Subtype Selective Substrates for Histone Deacetylases
Heltweg, B., Dequiedt, F., Marshall, B. L., Brauch, C., Yoshida, M., Nishino, N., Verdin, E., & Jung, M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0497592 · Cited by 126
The application of histone deacetylases inhibitors in glioblastoma
Chen, R., Zhang, M., Zhou, Y., Guo, W., Yi, M., Zhang, Z., Ding, Y., & Wang, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01643-6 · Cited by 133
Zhang, N., Jin, M., Wang, K., Zhang, Z., Shah, N. P., & Wei, H. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.119043 · Cited by 130
Verma, A., Bhagchandani, T., Rai, A., Nikita, N., Sardarni, U. K., Bhavesh, N. S., Gulati, S., Malik, R., & Tandon, R. (2024) · ACS Omega · doi:10.1021/acsomega.3c05846 · Cited by 136
Menegola, E., Renzo, F. D., Broccia, M. L., Prudenziati, M., Minucci, S., Massa, V., & Giavini, E. (2005) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20053 · Cited by 124
Rechache, N. S., Wang, Y., Stevenson, H. S., Killian, J. K., Edelman, D. C., Merino, M., Zhang, L., Nilubol, N., Stratakis, C. A., Meltzer, P. S., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3298 · Cited by 123
To, K. K. W., Polgar, O., Huff, L. M., Morisaki, K., & Bates, S. E. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0175 · Cited by 123
“Whereas differential display (59) or microarray analyses (60, 61) identify only 2% to 10% of expressed genes as sensitive to HDAC inhibitors, in this case, we have a gene responding to HDAC inhibition in one cell line but not in another.”
BackgroundRegulation of microglial inflammatory response by histone deacetylase inhibitors
Suuronen, T., Huuskonen, J., Pihlaja, R., Kyrylenko, S., & Salminen, A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02004.x · Cited by 124
“Potentiation was observed in transformed murine N9 microglial cells as well as in cultured rat primary microglia, which suggests that the effect is not limited to transformed cells (Marks et al. 2001; Johnstone 2002).”
BackgroundInfluentialPathil, A., Armeanu, S., Venturelli, S., Mascagni, P., Weiß, T. S., Gregor, M., Lauer, U. M., & Bitzer, M. (2006) · Hepatology · doi:10.1002/hep.21054 · Cited by 126
Matthews, G. M., Newbold, A., & Johnstone, R. W. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00005-7 · Cited by 128
Self-citationRole of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents
Dhuguru, J., & Skouta, R. (2020) · Molecules · doi:10.3390/molecules25071615 · Cited by 124
“HDAC inhibitors have, thus, evolved as a new class of anti-cancer agents because of their efficacy to arrest cell growth, cell differentiation, and cell death by apoptosis [88,89].”
BackgroundChoo, Q., Ho, P. C., Tanaka, Y., & Lin, H. (2010) · Rheumatology · doi:10.1093/rheumatology/keq108 · Cited by 130
Butchbach, M. E. R., Singh, J., Þorsteinsdóttir, M., Saieva, L., Slominski, E., Thurmond, J., Andrésson, T., Zhang, J., Edwards, J. D., Simard, L. R., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddp510 · Cited by 119
Itoh, H., & Inoue, M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00063 · Cited by 125
Furlan, A., Monzani, V., Reznikov, L. L., Leoni, F., Fossati, G., Modena, D., Mascagni, P., & Dinarello, C. A. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00020 · Cited by 120
“However, new synthetic HDAC inhibitors were developed primarily to treat cancer, by modulating the expression of pro-apoptotic genes that have been suppressed in malignant cells (2,3).”
BackgroundMethylation and acetylation in nervous system development and neurodegenerative disorders
Mattson, M. P. (2003) · Ageing Research Reviews · doi:10.1016/s1568-1637(03)00013-8 · Cited by 131
Rational design and validation of a Tip60 histone acetyltransferase inhibitor
Gao, C., Bourke, E., Scobie, M., Famme, M. A., Koolmeister, T., Helleday, T., Eriksson, L. A., Lowndes, N. F., & Brown, J. A. L. (2014) · Scientific Reports · doi:10.1038/srep05372 · Cited by 125
The Design of Inhibitors for Medicinally Relevant Metalloproteins
Jacobsen, F. E., Lewis, J. A., & Cohen, S. M. (2007) · ChemInform · doi:10.1002/chin.200719261 · Cited by 117
Histone deacetylase inhibitors and cancer: from cell biology to the clinic
Hess‐Stumpp, H. (2005) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2004.12.010 · Cited by 128
Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases
Berger, A., Venturelli, S., Kallnischkies, M., Böcker, A., Busch, C., Weiland, T., Noor, S., Leischner, C., Weiß, T. S., Lauer, U. M., et al. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2012.07.001 · Cited by 116
“Due to the fact that, in many cancer tissues, an overexpression of HDAC enzymes contributes to the shut-down of regulatory genes, it is of great interest to identify and investigate both synthetic and natural HDAC inhibitors (HDACis) as potential new anticancer drugs [21,22].”
BackgroundIn vitro assays for the determination of histone deacetylase activity
Heltweg, B., Trapp, J., & Jung, M. (2005) · Methods · doi:10.1016/j.ymeth.2005.03.003 · Cited by 116
Das Gupta, K., Shakespear, M. R., Iyer, A., Fairlie, D. P., & Sweet, M. J. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2015.46 · Cited by 115
Post-Translational Modifications in NETosis and NETs-Mediated Diseases
Hamam, H. J., & Palaniyar, N. (2019) · Biomolecules · doi:10.3390/biom9080369 · Cited by 122
“In fact, they are overexpressed in cancer cells, where HDACs regulate gene expression by silencing tumor suppressor genes [192].”
BackgroundExpression and Function of Histone Deacetylases in Rheumatoid Arthritis Synovial Fibroblasts
HORIUCHI, M., MORINOBU, A., CHIN, T., SAKAI, Y., KUROSAKA, M., & KUMAGAI, S. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.081115 · Cited by 114
Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease
Adwan, L., & Zawia, N. H. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.03.010 · Cited by 115
“lung and colon cancer (Johnstone, 2002; Barneda-Zahonero & Parra, 2012; New et al., 2012).”
Yang, Y., Zhao, Y., Liao, W., Yang, J., Wu, L., Zheng, Z., Yu, Y., Zhou, W., Li, L., Feng, J., et al. (2009) · Neoplasia · doi:10.1593/neo.81358 · Cited by 114
“Histone deacetylase inhibitors are also reported to induce acetylation of nonhistone proteins [36,37] and to have the ability to acetylate hyperacetylated nucleosome core histones [30] or to demethylate DNA [38].”
BackgroundChristiansen, A. J., West, A., Banks, K.-M., Haynes, N. M., Teng, M. W., Smyth, M. J., & Johnstone, R. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011037108 · Cited by 114
“HDACis are a promising class of anticancer agents that can selectively kill tumor cells, block cell cycle progression, and induce cellular differentiation (13, 14).”
BackgroundSelf-citationCha, T.-L., Chuang, M.-J., Wu, S.-T., Sun, G.-H., Chang, S.-Y., Yu, D.-S., Huang, S.-M., Huan, S. K.-H., Cheng, T.-C., Chen, T.-T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1918 · Cited by 111
Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance
Staub, J. K., CHIEN, J. R., Pan, Y., Qian, X., Narita, K., Aletti, G. D., Scheerer, M. F., Roberts, L. R., Molina, J. R., & Shridhar, V. (2007) · Oncogene · doi:10.1038/sj.onc.1210300 · Cited by 125
“…chemical agents commonly used to modulate the expression of silenced genes in cancer cells are 5-aza20-deoxycytitdine (5-aza-dC), which is an inhibitor of DNA methylation and trichostatin A (TSA), an inhibitor of histone deacetylation (Marks et al., 2001; Johnstone, 2002; Yamashita et al., 2002).”
BackgroundCancer epigenetics: above and beyond
Brait, M., & Sidransky, D. (2011) · Toxicology Mechanisms and Methods · doi:10.3109/15376516.2011.562671 · Cited by 135
Inhibition of HDAC1 and DNMT1 Modulate RGS10 Expression and Decrease Ovarian Cancer Chemoresistance
Çaçan, E., Ali, M. W., Boyd, N., Hooks, S. B., & Greer, S. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087455 · Cited by 119
“HDAC and DNMT1 inhibitors induce a potent anticancer response by inhibiting histone deacetylation and DNA hypermethylation [75–77].”
BackgroundHDAC inhibitors in experimental liver and kidney fibrosis
Beneden, K. V., Mannaerts, I., Pauwels, M., Branden, C. V. D., & van Grunsven, L. A. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-1 · Cited by 114
“The structural diversity among HDAC inhibitors suggests that the mechanism of action may involve other interactions on top of its HDAC contact to account for the deacetylase activity of the inhibitor [86,87,91].”
BackgroundMicrobiota-derived short-chain fatty acids: Implications for cardiovascular and metabolic disease
Lu, Y., Zhang, Y., Zhao, X., Shang, C., Xiang, M., Li, L., & Cui, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.900381 · Cited by 125
“Besides serving as intestinal fuel (butyrate) or nutrition for colonic mucosa (36, 37), with the development of human diseases, the function of SCFAs also existed in intestinal epithelial cells, immune cells, and adipocytes.”
BackgroundIn Vivo Effects of Histone‐Deacetylase Inhibitor Trichostatin‐A on Murine Spermatogenesis
Fenic, I., Sonnack, V., Failing, K., Bergmann, M., & Steger, K. (2004) · Journal of Andrology · doi:10.1002/j.1939-4640.2004.tb02859.x · Cited by 109
Konsoula, R., & Jung, M. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.05.001 · Cited by 108
“N IH -PA Author M anuscript N IH -PA Author M anuscript Actions of HDAC inhibitors (HDACIs) often result in cell cycle arrest, differentiation and apoptosis in numerous transformed cell lines in culture and in vivo (Johnstone, 2002; McLaughlin and La Thangue, 2004; Minucci and Pelicci, 2006).”
BackgroundFurchert, S. E., Lanvers‐Kaminsky, C., Juürgens, H., Jung, M., Loidl, A., & Frühwald, M. C. (2007) · International Journal of Cancer · doi:10.1002/ijc.22401 · Cited by 119
“Trichostatin A (TSA) has shown potential in vitro at nanomolar concentrations.(7) TSA increases acetylation of histone H3 and induces apoptosis in tumor cells.”
BackgroundCorminboeuf, C., Hu, P., Tuckerman, M. E., & Zhang, Y. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0600882 · Cited by 107
Microbiota–Host Transgenomic Metabolism, Bioactive Molecules from the Inside: Miniperspective
Turroni, S., Brigidi, P., Cavalli, A., & Candela, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00244 · Cited by 108
Marquard, L., Gjerdrum, L. M., Christensen, I. J., Jensen, P. B., Sehested, M., & Ralfkiaer, E. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03109.x · Cited by 107
“HDACs normally function together with cofactors that recruit HDACs to target genes(28) and improper recruitment of HDACs by these cofactors has been identified as a mechanism for the development of malignancy.(29,30) Fusion proteins generated by chromosomal translocations have also shown improper HDAC recruitment, par…”
BackgroundLiu, T., Tee, A. E., Porro, A., Smith, S. A., Dwarte, T. M., Liu, P. Y., Iraci, N., Sekyere, E. O., Haber, M., Norris, M. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705524104 · Cited by 125
Mai, A., Massa, S., Ragno, R., Cerbara, I., Jesacher, F., Loidl, P., & Brosch, G. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021070e · Cited by 104
Deacetylation of Nonhistone Proteins by HDACs and the Implications in Cancer
Peng, L., & Seto, E. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-21631-2_3 · Cited by 113
Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis
Higashiyama, R., Miyaki, S., Yamashita, S., Yoshitaka, T., Lindman, G., Ito, Y., Sasho, T., Takahashi, K., Lotz, M., & Asahara, H. (2009) · Modern Rheumatology · doi:10.1007/s10165-009-0224-7 · Cited by 113
Gao, H., Wen, J.-J., Hu, J., Nie, Q., Chen, H., Nie, S., Xiong, T., & Xie, M. (2019) · Food Bioscience · doi:10.1016/j.fbio.2019.03.007 · Cited by 111
Bonfils, C., Kalita, A., Dubay, M., Siu, L. L., Carducci, M. A., Reid, G., Martell, R. E., Besterman, J. M., & Li, Z. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4427 · Cited by 99
“11 (5) Compound A >50 (3) >50 (4) >50 (4) >50 (4)”
Ng, Y., Barhoumi, R., Tjalkens, R. B., Fan, Y., Kolar, S. S. N., Wang, N., Lupton, J. R., & Chapkin, R. S. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi163 · Cited by 111
“Butyrate can induce cellular oxidative stress and can modulate cellular gene expression leading to changes in cell cycle arrest, maturation, differentiation, as well as apoptosis (36-38, 42).”
BackgroundChen, J., Ghazawi, F. M., Bakkar, W., & Li, Q. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-71 · Cited by 112
“Numerous studies have shown that, through its chromatin remodeling activities, HDAC inhibitors are capable of modulating gene transcription involved in various cellular processes such as cell cycle progression, differentiation and apoptosis [15].”
BackgroundBowers, A. A., West, N., Newkirk, T. L., Troutman-Youngman, A. E., Schreiber, S. L., Wiest, O., Bradner, J. E., & Williams, R. M. (2009) · Organic Letters · doi:10.1021/ol900078k · Cited by 103
Hsieh, T.-H., Hsu, C., Tsai, C.-F., Long, C., Wu, C., Wu, D., Lee, J.-N., Chang, W.-C., & Tsai, E. (2014) · Molecular Therapy · doi:10.1038/mt.2014.247 · Cited by 110
MicroRNA-222 regulates MMP-13 via targeting HDAC-4 during osteoarthritis pathogenesis
Song, J., Jin, E., Kim, D., Kim, K. Y., Chun, C. H., & Jin, E. (2014) · BBA Clinical · doi:10.1016/j.bbacli.2014.11.009 · Cited by 108
Das, C. M., Aguilera, D. G., Vasquez, H., Prasad, P., Zhang, M., Wolff, J. E. A., & Gopalakrishnan, V. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9402-7 · Cited by 102
“These agents induce hyperacetylation of chromatin and reactivate the expression of aberrantly silenced genes involved in cell cycle control (p21, p27, p53, and p38MAP2 kinase) and apoptosis (caspases, Bid, Bax, and APAF-1) [25, 30, 32, 33].”
Histone Deacetylase Inhibitors as Novel Anticancer Therapeutics
Walkinshaw, D. R., & Yang, X. (2008) · Current Oncology · doi:10.3747/co.v15i5.371 · Cited by 114
Galloway, T. J., Wirth, L. J., Colevas, A. D., Gilbert, J., Bauman, J. E., Saba, N. F., Raben, D., Mehra, R., Ma, A. W., Atoyan, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2820 · Cited by 102
“Furthermore, epigenetic changes, such as acetylation of histones and nonhistone proteins, affect chromatin structure, affecting gene expression and contributing to cancer initiation, progression, and treatment resistance (8), and may be amenable to treatment with HDAC inhibitors.”
Watanabe, K., Okamoto, K., & Yonehara, S. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401507 · Cited by 108
Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer
Diyabalanage, H. V. K., Granda, M. L., & Hooker, J. M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.018 · Cited by 112
Lü, Q., Yang, Y., Chen, C., Davis, M. E., Byrd, J. C., Etherton, M. R., Umar, A., & Chen, C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303655 · Cited by 117
Lee, J.-H., Park, J.-H., Jung, Y., Kim, J.-H., Jong, H.-S., Kim, T.-Y., & Bang, Y.-J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0419 · Cited by 101
“HDACIs are classified into hydroxamic acid, short-chain fatty acid, benzamide, cyclic tetrapeptide, and hybrid compounds according to their chemical structure (25, 45, 46).”
BackgroundTang, H., Wang, X. S., Huang, X., Roth, B. L., Butler, K. V., Kozikowski, A. P., Jung, M., & Tropsha, A. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800366f · Cited by 109
Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer
Fallah, M., Davoodvandi, A., Nikmanzar, S., Aghili, S., Mirazimi, S. M. A., Aschner, M., Rashidian, A., Hamblin, M. R., Chamanara, M., Naghsh, N., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112024 · Cited by 108
Baud, M. G. J., Leiser, T., Haus, P., Samlal, S., Wong, A. C., Wood, R. J., Petrucci, V., Gunaratnam, M., Hughes, S. M., Buluwela, L., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2016182 · Cited by 100
Structure-Based Optimization of Phenylbutyrate-Derived Histone Deacetylase Inhibitors
Lu, Q., Wang, D.-S., Chen, C.-S., Hu, Y.-D., & Chen, C.-S. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503749 · Cited by 100
Mai, A., Rotili, D., Massa, S., Brosch, G., Simonetti, G., Passariello, C., & Palamara, A. T. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.028 · Cited by 109
The molecular mechanism of HDAC inhibitors in anticancer effects.
Bi, G., & Jiang, G. (2006) · PubMed · Cited by 114
HDAC inhibitors: A new promising drug class in anti-aging research
Pasyukova, E. G., & Vaiserman, A. M. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.08.008 · Cited by 99
“HDAC inhibitors are considered to be very promising candidates in cancer treatments since these agents preferentially kill neoplastic cells and are relatively non-toxic to normal cells (Johnstone, 2002), though the molecular mechanisms of this selectivity remain to be elucidated.”
BackgroundPan, L., Matloob, A. F., Du, J., Pan, H., Dong, Z., Zhao, J., Feng, Y., Zhong, Y., Huang, B., & Lu, J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07542.x · Cited by 97
Shen, W., Wang, C., Xia, L., Fan, C., Dong, H., Deckelbaum, R. J., & Qi, K. (2014) · Scientific Reports · doi:10.1038/srep05282 · Cited by 97
Park, J., Kim, S.-H., Choi, M.-C., Lee, J., Oh, D., Im, S., Bang, Y., & Kim, T.-Y. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.056 · Cited by 99
Hu, J., & Colburn, N. H. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0070 · Cited by 98
“Our results also suggest an explanation for the observation that among the genes suppressed by HDAC inhibitors several are known NF-nB-controlled target genes, such as Bcl-xL , Bcl-2 , c-myb , c-myc , IL-1 , IL-6 , and TNF-a (6, 43, 51, 52).”
BackgroundResultCancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment
Polireddy, K., & Chen, Q. (2016) · Journal of Cancer · doi:10.7150/jca.14922 · Cited by 120
“This compaction blocks gene transcription and inhibits differentiation (179, 180).”
BackgroundCurrent and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
Lansigan, F., & Foss, F. M. (2010) · Drugs · doi:10.2165/11532190-000000000-00000 · Cited by 104
“HATs transfer acetyl groups to lysine residues, which results in expansion of chromatin and increased accessibility of regulatory proteins to DNA, whereas HDACs catalyse the removal of acetyl modification, leading to chromatin condensation and transcriptional repression.([65,66])”
Zhou, W., Zhang, D., Li, Z., Jiang, H., Li, J., Ren, R., Gao, X., Li, J., Wang, X., Wang, W., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02882-7 · Cited by 108
“As an HDACi, in vitro studies have indicated that butyrate can inhibit the growth of colon, prostate, and cervical carcinomas by inducing apoptosis, differentiation and cell-cycle arrest [39].”
BackgroundMechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells
Chüeh, A. C., Tse, J. W. T., Tögel, L., & Mariadason, J. M. (2015) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5863 · Cited by 109
“These effects are mediated through a number of mechanisms, including transcriptional changes, increased production of reactive oxygen species, altered signaling, and aberrant mitosis (15, 22, 76, 106).”
Wu, Q., Cheng, Z., Zhu, J., Xu, W., Peng, X., Chen, C., Li, W., Wang, F., Cao, L., Yi, X., et al. (2015) · Scientific Reports · doi:10.1038/srep09520 · Cited by 102
Sun, P., Xia, S., Lal, B., Eberhart, C. G., Quinones-Hinojosa, A., Maciaczyk, J., Matsui, W., DiMeco, F., Piccirillo, S. M., Vescovi, A. L., et al. (2009) · Stem Cells · doi:10.1002/stem.89 · Cited by 98
“Oncogenesis is associated with a relative decrease in histone acetylation, leading to the transcriptional repression of tumor suppressor genes, a common event contributing to tumor formation [28].”
BackgroundXia, S., Li, X., Johnson, T., Seidel, C. W., Wallace, D. P., & Li, R. (2010) · Development · doi:10.1242/dev.049437 · Cited by 98
“The anti-proliferative effect of HDAC inhibitors is in fact the basis for clinical studies of these molecules in anticancer therapies (Johnstone, 2002).”
BackgroundWill broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
Karagiannis, T. C., & El‐Osta, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404464 · Cited by 107
Zhang, Y., Ying, J. B., Hong, J. J., Li, F., Fu, T. T., Yang, F. Y., Zheng, G. X., Yao, X., Lou, Y., Qiu, Y., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00729 · Cited by 97
Diet as a Modulator of Intestinal Microbiota in Rheumatoid Arthritis
Dourado, E., Ferro, M., Guerreiro, C. S., & Fonseca, J. E. (2020) · Nutrients · doi:10.3390/nu12113504 · Cited by 106
“Butyrate and propionate are known to act as histone deacetylase inhibitors [47].”
BackgroundLiao, L., He, Y., Li, S.-J., Zhang, G.-G., Yu, W., Yang, J., Huang, Z., Zheng, C., He, Q., Li, Y., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4124 · Cited by 98
Ramírez, T., Brocher, J., Stopper, H., & Hock, R. (2007) · Chromosoma · doi:10.1007/s00412-007-0133-5 · Cited by 95
“In addition, methyl-CpG binding proteins, such as MECP2, MBD1, 2, and 3, bind to methylated DNA and recruit HDACs to form a tightly condensed chromatin structure (Johnstone 2002).”
BackgroundArmeanu, S., Pathil, A., Venturelli, S., Mascagni, P., Weiß, T. S., Göttlicher, M., Gregor, M., Lauer, U. M., & Bitzer, M. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.10.020 · Cited by 97
“Some of these substances entered clinical trials and completed phase I [12,16], but a drug with a favourable in vivo profile for HCC patients has not been investigated yet [17].”
BackgroundNonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases
Heltweg, B., Dequiedt, F., Verdin, E. M., & Jung, M. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(03)00276-8 · Cited by 110
“1016/S0003-2697(03)00276-8 scriptional repression which may also induce reversal of the malignant phenotype [6], and several HDAC inhibitors are already in clinical trials for the treatment of cancer [7].”
Zhang, X., Wharton, W., Yuan, Z., Tsai, S.-C., Olashaw, N., & Seto, E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5106-5118.2004 · Cited by 95
Wang, L., Li, C., Huang, Q., Fu, X., & Liu, R. H. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.11.021 · Cited by 98
Depetter, Y., Geurs, S., Vreese, R. D., Goethals, S., Vandoorn, E., Laevens, A., Steenbrugge, J., Meyer, E., Tullio, P. D., Bracke, M., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32169 · Cited by 99
Epigenetic Dysregulation in Cancer
Muntean, A. G., & Hess, J. L. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081142 · Cited by 113
“Tumor cells generally show higher sensitivity to HDACi than normal cells.(93) HDACi have shown particular efficacy against cutaneous T cell lymphomas and one, suberoylanilide hydroxamic acid (vorinostat), has been Food and Drug Administration approved for this application.”
BackgroundPavlik, C. M., Wong, C. Y. B., Ononye, S. N., Lopéz, D., Engene, N., McPhail, K. L., Gerwick, W. H., & Balunas, M. J. (2013) · Journal of Natural Products · doi:10.1021/np400198r · Cited by 103
LER, S. Y., Leung, C. H., Khin, L. W., Lu, G., Salto‐Tellez, M., Hartman, M., Iau, P. T. C., Yap, C. T., & Hooi, S. C. (2015) · Oncology Reports · doi:10.3892/or.2015.4263 · Cited by 100
“They are ubiquitously expressed in many tissues and since they lack nuclear export signals, they are found exclusively in the nucleus (5).”
BackgroundVandermeers, F., Hubert, P., Delvenne, P., Mascaux, C., Grigoriu, B. D., Burny, A., Scherpereel, A., & Willems, L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1579 · Cited by 94
Kulp, S. K., Chen, C., Wang, D.-S., Chen, C., & Chen, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0429 · Cited by 105
RetractedCurrent trends in protein acetylation analysis
Diallo, I., Seve, M., Cunin, V., Minassian, F., Poisson, J.-F., Michelland, S., & Bourgoin-Voillard, S. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1559061 · Cited by 89
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma
Lu, Y., Kashida, Y., Kulp, S. K., Wang, Y.-C., Wang, D.-S., Hung, J., Tang, M., Lin, Z., Chen, T.-J., Cheng, A., et al. (2007) · Hepatology · doi:10.1002/hep.21804 · Cited by 97
Histone Deacetylase Inhibitors for Cancer Therapy
Kim, T., Bang, Y., & Robertson, K. D. (2006) · Epigenetics · doi:10.4161/epi.1.1.2644 · Cited by 108
Metadata
- Authors
- Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971621147
- Cited by
- 1,515
- References
- 121
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 23 · 2023: 46 · 2022: 35 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 38 · 2017: 65 · 2016: 50 · 2015: 64 · 2014: 54 · 2013: 81 · 2012: 94
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, aberrant transcription, tumor cell growth inhibition, cancer therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Cell Differentiation, Chromatin, Clinical Trials as Topic, Enzyme Inhibitors, Histones, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.